Entera Bio Ltd (ENTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $525.90M
Last updated: Nov 17, 2026 at 4:26 PM ET
Entera Bio Ltd (ENTX) Statistics
Entera Bio (ENTX) has a market cap of $525.90M and an enterprise value of $260.39M. Its share count is up 208.08% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 50.49% below the market cap, as cash exceeds debt.
| Market Cap | $525.90M |
|---|---|
| Enterprise Value | $260.39M |
| Latest price (Nov 17, 2026) | $3.00 |
Key Dates
The next earnings report is expected on Mar 25, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 25, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 6, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is up 10.70% over 52 weeks and trades 3.45% above its 50-day average.
| Beta (1Y) | 0.86 |
|---|---|
| 52-Week Change | +10.70% |
| 1-Month Change | +2.04% |
| 3-Month Change | -3.54% |
| 6-Month Change | +136.22% |
| 5-Year Change | -24.88% |
| Total Return (1Y) | +10.70% |
| Total Return (5Y CAGR) | -2.59% |
| Return vs SPY (1Y) | +3.83% |
| Max Drawdown (1Y) | -62.69% |
| Max Drawdown (3Y) | -68.15% |
| Sharpe Ratio (1Y) | 0.13 |
| Correlation with SPY (1Y) | 0.11 |
| 50-Day Average | $2.90 |
| 200-Day Average | $2.00 |
| 52-Week Range | $0.91 to $4.20 |
| RSI (14 Days) | 48.7 |
| Average Volume (20 Days) | 262.69K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 128.41x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 128.41x |
|---|---|
| Quick Ratio | 128.41x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on invested capital is -8.46% over the last 12 months, against a 5-year average of -66.97%.
| Return on Equity (ROE) | -10.73% |
|---|---|
| Return on Assets (ROA) | -10.62% |
| Return on Invested Capital (ROIC) | -8.46% |
| Return on Capital Employed (ROCE) | -10.71% |
| ROE (5Y Average) | -91.24% |
| ROA (5Y Average) | -79.03% |
| ROIC (5Y Average) | -66.97% |
Scores
ENTX has a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 2 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Gross Profit | -$7.00K |
| Operating Income | -$18.41M |
| Pretax Income | -$29.43M |
| Net Income | -$29.43M |
| EBIT | -$29.43M |
| Reported EPS (TTM) | -$0.38 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 99.00% of the $277.04M in total assets.
| Cash and Equivalents | $265.88M |
|---|---|
| Total Debt | $378.00K |
| Net Cash | $265.50M |
| Net Cash Per Share | $1.83 |
| Working Capital | $274.31M |
| Shareholder Equity | $274.28M |
| Book Value Per Share | $1.89 |
| Total Assets | $277.04M |
| Total Liabilities | $2.76M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $51.00K of capital spending, operating cash flow left -$15.84M of free cash flow.
| Operating Cash Flow | -$15.79M |
|---|---|
| Capital Expenditures | $51.00K |
| Free Cash Flow | -$15.84M |
| FCF Per Share | -$0.09 |
| Depreciation and Amortization | $32.00K |
Trailing 12 months through Sep 30, 2026.
Growth
Revenue fell 32.07% a year over 3 years.
| Revenue Growth (3Y CAGR) | -32.07% |
|---|---|
| Revenue Growth (5Y CAGR) | -35.11% |
| Book Value Per Share Growth (2Y CAGR) | -9.93% |
| Tangible Book Per Share Growth (2Y CAGR) | -9.93% |
Dividends and Yields
ENTX does not pay a dividend. Its free cash flow yield is -3.64%.
| FCF Yield | -3.64% |
|---|---|
| Buyback Yield | 3.28% |
| Shareholder Yield | 3.28% |
Peer Position
Against 5 similar companies, ENTX has the 2nd highest ROIC.
ROICPeer median -53.81%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -1.95%
| ROIC | -8.46% vs -53.81% median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | -100.00% vs -1.95% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About ENTX
What is ENTX's market cap?
Entera Bio has a market cap of $525.90M. Its enterprise value, which adds debt and subtracts cash, is $260.39M.
How many shares of ENTX are outstanding?
Entera Bio has 145.08M shares outstanding. The count is up 208.08% from a year earlier.
Does ENTX pay a dividend?
No. Entera Bio does not pay a dividend.
How much debt does ENTX have?
Entera Bio has $378.00K of total debt and $265.88M of cash and equivalents, a net cash position of $265.50M.
ENTX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors